Zealand Pharma converts rusfertide royalty into $100M from Royalty Pharma

What's the deal? Zealand Pharma will receive $100 million from Royalty PharmaDealroom has a profile for this one. Try Dealroom → in exchange for its economic interests related to rusfertide (PTG-300), including rights to a 1% royalty on potential future global net sales and regulatory and commercial milestones. The agreement provides $50 million at closing and the remaining $50 million on the first anniversary of closing.

Why now? The transaction converts a future royalty stream into immediate capital that Zealand Pharma says it will redeploy against growth opportunities. Zealand Pharma retains a 0.25% royalty on annual global net sales above $1.5 billion, while Royalty Pharma retains a 0.75% royalty above that threshold. Rusfertide is under regulatory review as a potential treatment for polycythemia vera.

Read more: AP News · Zealand Pharma